论文部分内容阅读
使用低浓度的重组人白介素-2（rhIL－2）诱导的胎脾LAK细胞杀伤髓系白血病细胞系HL－60和KG－Ia51Cr释放研究表明，在不同的胎脾LAK效应细胞和靶细胞比（E：T）条件下，对两种分化程度不同的白血病细胞杀伤能力也不同。E：T越高杀伤能力越强，HL－60P＜0．01，KG-IaP＜0．005。胎脾LAK细胞杀伤HL－60平均杀伤率为55．44％±11．23％，KG－Ia平均杀伤率为22．54％±8．22％，两者比较P＜0．005。在相同E：T时对HL－60和KG－Ia杀伤活性比较P＜0．002。结果提示，胎脾LAK细胞对分化程度好的白血病细胞HL－60杀伤能力显著高于分化差的原始白血病细胞KG－Ia，E：T越大杀伤活性越强。因而为LAK细胞治疗髓系白血病提供了参考。
The use of low concentrations of recombinant human interleukin-2 (rhIL-2)-induced fetal spleen LAK cells to kill myeloid leukemia cell lines HL-60 and KG-Ia51Cr release studies showed that in different fetal spleen LAK effector cells and target cell ratio ( Under conditions of E:T), the ability of killing leukemia cells with different degrees of differentiation is also different. The higher the E:T, the stronger the killing ability, HL-60P<0.01, KG-IaP<0.005. The average killing rate of HL-60 in fetal spleen LAK cells was 55.44%±11.23%, and the average KG-Ia killing rate was 22.54%±8.22%. The comparison between them was P<0.005. The killing activity of HL-60 and KG-Ia at the same E:T comparison P<0.002. The results suggest that the ability of fetal spleen LAK cells to kill HL-60 leukemia cells with better differentiation is significantly higher than that of poorly differentiated primary leukemic cells KG-Ia. The larger the E:T, the stronger the killing activity. This provides a reference for LAK cells to treat myeloid leukemia.